INmune Bio's CORDStrom Gets Written Alignment on UK Conditional Marketing Authorization Application

MT Newswires Live

Jun 23

INmune Bio's (INMB) CORDStrom cell therapy in recessive dystrophic epidermolysis bullosa has received written alignment from the UK Medicines & Healthcare products Regulatory Agency on its planned 2026 conditional marketing authorization application, the company said Tuesday.

The UK healthcare body noted that while the MissionEB phase 2 data did not show durable wound closure or sustained reduction in total wound burden after treatment cessation, it could support the positioning as chronic or intermittent supportive therapy for the blistering disorder, the company said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2645839505"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2645839505\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2645839505?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-23 20:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645839505","market":"sg","top_or_hot":-1,"title":"INmune Bio's CORDStrom Gets Written Alignment on UK Conditional Marketing Authorization Application","media":"MT Newswires Live","content":"<html><body><p> INmune Bio's (INMB) CORDStrom cell therapy in recessive dystrophic epidermolysis bullosa has received written alignment from the UK Medicines &amp; Healthcare products Regulatory Agency on its planned 2026 conditional marketing authorization application, the company said Tuesday.</p><p>The UK healthcare body noted that while the MissionEB phase 2 data did not show durable wound closure or sustained reduction in total wound burden after treatment cessation, it could support the positioning as chronic or intermittent supportive therapy for the blistering disorder, the company said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>INmune Bio's CORDStrom Gets Written Alignment on UK Conditional Marketing Authorization Application</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nINmune Bio's CORDStrom Gets Written Alignment on UK Conditional Marketing Authorization Application\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-23 20:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> INmune Bio's (INMB) CORDStrom cell therapy in recessive dystrophic epidermolysis bullosa has received written alignment from the UK Medicines &amp; Healthcare products Regulatory Agency on its planned 2026 conditional marketing authorization application, the company said Tuesday.</p><p>The UK healthcare body noted that while the MissionEB phase 2 data did not show durable wound closure or sustained reduction in total wound burden after treatment cessation, it could support the positioning as chronic or intermittent supportive therapy for the blistering disorder, the company said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2645839505","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645839505","pubTimestamp":1782219230,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"INmune Bio's  CORDStrom cell therapy in recessive dystrophic epidermolysis bullosa has received written alignment from the UK Medicines & Healthcare products Regulatory Agency on its planned 2026 conditional marketing authorization application, the company said Tuesday.The UK healthcare body noted that while the MissionEB phase 2 data did not show durable wound closure or sustained reduction in total wound burden after treatment cessation, it could support the positioning as chronic or intermittent supportive therapy for the blistering disorder, the company said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","INMB":"INmune Bio Inc"},"translate_title":"INmune Bio的CORDStrom获得英国有条件营销授权申请的书面一致","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INMB":1},"content_text":"INmune Bio's (INMB) CORDStrom cell therapy in recessive dystrophic epidermolysis bullosa has received written alignment from the UK Medicines & Healthcare products Regulatory Agency on its planned 2026 conditional marketing authorization application, the company said Tuesday.The UK healthcare body noted that while the MissionEB phase 2 data did not show durable wound closure or sustained reduction in total wound burden after treatment cessation, it could support the positioning as chronic or intermittent supportive therapy for the blistering disorder, the company said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}